Acrivon Therapeutics, Inc. Acrivon Therapeutics, Inc. is listed today as Acrivon Therapeutics, Inc. : market value, financials and filings are on its company page.
Funding rounds 2 counted as startup funding. Open the number of investors for the round's details.
Funding rounds of Acrivon Therapeutics, Inc. Month Raised Raise Size Investors Sold Filing Nov 2021 $100 M No. 2 $50 to $250 million 13
Acrivon Therapeutics, Inc.: Raise no. 2, Nov 2021 × Investors in this round 13 investors had bought by the notice of Nov 23, 2021: 13 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $100 M of $100 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Eric Devroe · Executive Officer Erick Gamelin · Executive Officer Kristina Masson · Executive Officer, Director Peter Blume-Jensen · Executive Officer, Director Derek DiRocco · Director Marcin Czernik · Director Sharon Shacham · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Peter Blume-Jensen, President. Newest notice filed Nov 23, 2021. Read the notice at the SEC .
equity SEC Jan 2021 $16 M No. 1 $10 to $50 million 2
Acrivon Therapeutics, Inc.: Raise no. 1, Jan 2021 × Investors in this round 2 investors had bought by the notice of Feb 12, 2021: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $16 M of $16 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Eric Devroe · Executive Officer Kristina Masson · Executive Officer, Director Peter Blume-Jensen · Executive Officer, Director Marcin Czernik · Director Sharon Shacham · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Peter Blume-Jensen, President. Newest notice filed Feb 12, 2021. Read the notice at the SEC .
equity SEC
What its filings and its own website say, sentence by sentence, each with its source.
Acrivon Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2021).
SEC Form D · Nov 2021
The industry group it chose in its notices: Biotechnology.
SEC Form D · Nov 2021
No products or services of Acrivon Therapeutics, Inc. are on record.
No investor of Acrivon Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Largest shareholders today Institutions holding Acrivon Therapeutics, Inc. shares, as of Sep 30, 2026.
As of Sep 30, 2026
Executives and directors As the company named them in its notices. Directors of a funded startup are often partners of its investors.
People named by Acrivon Therapeutics, Inc. Name Role Named in Eric Devroe Executive officer Nov 2021 Erick Gamelin Executive officer Nov 2021 Kristina Masson Executive officer Nov 2021 Peter Blume-Jensen Executive officer Nov 2021 Derek DiRocco Director Nov 2021 Kristina Masson Director Nov 2021 Marcin Czernik Director Nov 2021 Peter Blume-Jensen Director Nov 2021 Sharon Shacham Director Nov 2021
Went public since 2022. Its SEC number is that of a company listed on a stock exchange.